Information Provided By:
Fly News Breaks for September 29, 2016
INCY
Sep 29, 2016 | 05:56 EDT
Raymond James analyst Reni Benjamin upgraded Incyte to Outperform with a $115 price target following the release of an abstract showcasing "positive" long-term follow-up results for epacadostat in melanoma. Epacadostat plus pembrolizumab, should ;the results be confirmed in the ongoing Phase III study, could effectively compete with ipilimumab and nivolumab, Benjamin tells investors in a research note.
News For INCY From the Last 2 Days
There are no results for your query INCY